Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Atezolizumab and Bevacizumab as Neoadjuvant Plus Adjuvant Treatment in HCC [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the combination of atezolizumab and bevacizumab as neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma; the trial …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Avastin (bevacizumab) (bevacizumab)
• Tecentriq (atezolizumab) (atezolizumab)

Snippet

Sponsor: Fundacion Clinic per a la Recerca Biomédica | Conditions: Resectable Hepatocellular Carcinoma | Phase 2 | Status: NOT_YET_RECRUITING